Vimseltinib
| CAS No. | 1628606-05-2 | Cat. No. | BCP44095 |
| Name | Vimseltinib | ||
| Synonyms | DCC-3014; DCC 3014; DCC3014; | ||
| Formula | C23H25N7O2 | M. Wt | 431.49 |
| Description | Vimseltinib, also known as DCC-3014, is a potent and orally active inhibitor of the tyrosine kinase receptor colony stimulating factor 1 receptor (CSF1R; CSF-1R; C-FMS; CD115; M-CSFR), with potential antineoplastic, macrophage checkpoint-inhibitory and immunomodulating activities. Upon administration, DCC-3014 targets and binds to CSF1R expressed on monocytes, macrophages, and osteoclasts and inhibits the binding of the CSF1R ligands colony-stimulating factor-1 (CSF-1) and interleukin-34 (IL-34), to CSF1R. This prevents CSF1R activation and CSF1R-mediated signaling in these cells. This blocks the production of inflammatory mediators by macrophages and monocytes and reduces inflammation. | ||
| Pathways | Angiogenesis/Protein Tyrosine Kinase | ||
| Targets | c Kit cFMS | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.